CN105802923B - A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof - Google Patents
A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof Download PDFInfo
- Publication number
- CN105802923B CN105802923B CN201610232296.9A CN201610232296A CN105802923B CN 105802923 B CN105802923 B CN 105802923B CN 201610232296 A CN201610232296 A CN 201610232296A CN 105802923 B CN105802923 B CN 105802923B
- Authority
- CN
- China
- Prior art keywords
- gene
- virus
- poliovirus
- sample particle
- dual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002245 particle Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 241000700605 Viruses Species 0.000 title claims description 42
- 201000010099 disease Diseases 0.000 title claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 16
- 210000000278 spinal cord Anatomy 0.000 title claims description 14
- 210000004884 grey matter Anatomy 0.000 title claims description 13
- 241000991587 Enterovirus C Species 0.000 claims abstract description 42
- 208000000474 Poliomyelitis Diseases 0.000 claims abstract description 30
- 241000238631 Hexapoda Species 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 239000013612 plasmid Substances 0.000 claims description 33
- 238000005457 optimization Methods 0.000 claims description 19
- 230000009466 transformation Effects 0.000 claims description 10
- 108020004705 Codon Proteins 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 7
- 230000009977 dual effect Effects 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 4
- 241000701447 unidentified baculovirus Species 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000255993 Trichoplusia ni Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 16
- 230000014509 gene expression Effects 0.000 abstract description 13
- 241000897111 recombinant polioviruses Species 0.000 abstract description 8
- 229960001539 poliomyelitis vaccine Drugs 0.000 abstract description 3
- 230000008521 reorganization Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 206010033799 Paralysis Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101100388690 Plasmodium falciparum (isolate K1 / Thailand) MEF-1 gene Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 229940124867 Poliovirus vaccine Drugs 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 101710140962 Capsid scaffolding protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000027889 monkey disease Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000006995 paralytic poliomyelitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to field of biotechnology, and in particular to a kind of I type of recombinant poliovirus, II type and III virus-like particle, and further disclose preparation method and its in the application for preparing pharmaceutical vaccine field.The method of preparation and reorganization poliovirus sample particle of the present invention, I type of polio, II type and III virus-like particle are successfully prepared in insect expression system, and I type of the polio, II type and III virus-like particle can be effectively used for preparing the polio vaccine based on virus-like particle.
Description
Technical field
The invention belongs to field of biotechnology, and in particular to a kind of I type of recombinant poliovirus, II type and III type virus-like
Particle, and further disclose preparation method and its in the application for preparing pharmaceutical vaccine field.
Background technique
Polio (Poliomyelitis) is one kind caused by poliovirus (Poliovirus, PV)
Acute infectious disease can seriously endanger the health of children.Poliovirus invades the nervous system of people, can be in a few hours
Inside body is caused to paralyse completely;Poliovirus can also be entered in vivo by oral cavity and be bred in enteron aisle, caused
Initial symptoms can behave as that fever, out of strength, headache, vomiting, neck is stiff and limbs pain.It is nearly all in not immune crowd
May be infected polio per capita has a few peoples to will appear paralysis symptom in the infected, since the symptom is apt to occur in infant,
Therefore it is commonly called as infantile paralysis again.Every 200 cases of infection just have an example to lead to irreversible paralysis (paralysis of usually two legs),
In paralysis case, there are about the patients of 5-10% can death due to paralysis of respiratory muscle.
Poliovirus belongs to the enterovirus genus of picornavirus (Picornaviridae)
(Enterovirus).Poliovirus structure is positive icosahedral structure of virus, and diameter is about 27-30nm, no capsule structure.
The genome of poliovirus is single-stranded positive RNA, by 5 ' noncoding regions, the area P1, the area P2, the area P3 and 3 ' non-coding district's groups
At.Wherein, the structural proteins P1 precursor of P1 coding virus can be cut into VP0, VP1 and VP3 by the protease precursor 3CD of virus
Structural proteins.These three albumen and viral RNA form virion, and VP0 is further cracked into VP2 and VP4 in assembling, complete
The assembling of mature virion.
Poliovirus is divided into I type, II type and III type according to serotype.Wherein I type polio is in 3 types
Most neural invasion in type, most polio are popular and endemic conditions case is caused by I type polio
, it is secondly respectively III type and II type, and Cross immunogenicity effect is had no between three kinds of serotypes.
Currently, what is mainly taken is based on vaccine inoculation clinically for the treatment of polio there is no specific drug
Precautionary measures.What is generally used both at home and abroad at present has inactivated vaccine (Inactivated for the vaccine that guards against poliomyelities
Poliovirus vaccine, IPV) and oral attenuated vaccine (Oral poliovirus vaccine, OPV).Wherein IPV is
The mixture being made of 3 seed type polioviruses by cell culture, harvest supernatant, purifying and formalin-inactivated etc. and
The vaccine of preparation.It is good that IPV vaccine compares OPV immunological safety, but apparent enteron aisle local immunity cannot be formed by being inoculated with IPV,
And cost is significantly higher than OPV.Since IPV needs mass propgation live virus, in laboratory and preparatory phase, there is also let out
The danger of dew.Primary rhesus macaque also malicious (SV40) containing monkey disease in IPV simultaneously, in vaccine early stage production and use process
Nephrocyte studies have shown that SV40 can be such that the cell of culture converts, and can lead to animal and generate tumour.And OPV is to use ridge
Marrow poliovirus attenuated strain manufactured white solid sugar-pill for guarding against poliomyelities after being cultivated, harvesting virus liquid,
Its advantage is that cheap, but its there are gene reversion and it is pathogenic the problems such as.The widely used vaccine in China is at present
OPV vaccine, clinic display, main adverse reaction relevant to OPV is Vaccine-associated paralytic poliomyelitis (VAPP).Nian Ping
The disease incidence of equal VAPP is that every 1,000,000 population occurs 0.14, and the risk highest of VAPP occurs in immune deficiency crowd.
1988, the World Health Organization the whole world start " Poliomyelitis Eradication " action, by implement disease surveillance,
The strategies such as immunity inoculation, China are the circulation blocking for realizing Polio vaccine virus from nineteen ninety-five.It 2000, is defended through the world
Raw tissue confirmation, the West Pacific region including China has realized no ridge ash target substantially;To 2010, the whole world was only
The country for having 4 native country ridges ashes popular, wherein 3 and China border on, i.e. India, Pakistan and Afghanistan, to China's sufferer
Prevention and treatment also constitute certain hidden danger.Until today, the target of global Poliomyelitis Eradication still do not reach, only exist
2005-2009, Nigeria there have been Acute Flaccid Paralysis caused by 3660 Infected With Polioviruses In Vitros,
I type polio street strain Introduced cases epidemic situation also had occurred in autonomous region, Xinjiang of China Uygur in 2011.As it can be seen that China pair
The prevention and treatment of polio is not allowed still to loosen.
With the fast development of modern biotechnology, recombinant vaccine becomes new virus preventative vaccine in recent years
Main development trend.Wherein, the recombinant vaccine based on virus-like particle (Virus-like particles, VLPs) is standby
It is concerned.Virus-like particle is the hollow bead without viral nucleic acid that is formed by viral capsid proteins self assembly, have with
The same or similar steric configuration of natural viral capsid protein and epitope have very strong immunogenicity, can effective stimulus
Body generates humoral immunity and cellullar immunologic response.And since virus-like particle is free of virulent genome, do not have
Standby replication capacity, safety is better than traditional attenuated live vaccine and inactivated vaccine, so the appearance of virus sample particle vaccines
A new opportunity is provided to research and develop safer effective vaccine.
Summary of the invention
For this purpose, technical problem to be solved by the present invention lies in provide a kind of I type of recombinant poliovirus, II type and III type
Virus-like particle, and further disclose preparation method and its in the application for preparing pharmaceutical vaccine field.
In order to solve the above technical problems, the preparation method of recombining spinal cord grey matter disease virus sample particle of the present invention, packet
Include following steps:
(1) the P1 gene and 3CD gene for taking poliovirus are cloned into coexpression vector respectively, then by turning
Change the recombinant viral vector that competent cell obtains to express poliovirus sample particle;
(2) the recombinant viral vector transfection insect cell obtained with step (1) is obtained after culture containing coding virus-like
The recombinant virus of corpuscular protein gene;
(3) recombinant virus infection to the host cell that step (2) obtain is expanded to improve virus titer, with being followed by
The recombinant virus of kind high titre infects insect cell, to express above-mentioned P1 gene and 3CD gene, and obtains according to conventional purification method
Obtain poliovirus sample particle.
Preferably, in the step (1), the P1 gene and the 3CD gene are the Preference according to host cell
Carry out the gene of codon optimization.
The codon optimization, which refers to, is not changing wild poliovirus P1 albumen and 3CD Argine Monohydrochloride sequence
Under the premise of column, the codon of wild poliovirus P1 gene and 3CD gene is replaced with into insect cell preference
Codon.
In the step (1): the poliovirus includes I type, II type or III type virus, the polio
Virus I-form, II type, the P1 gene of III type virus and 3CD gene are belonging respectively to the Mahoney of wild poliovirus
Strain, MEF-1 plants and Saukett plants.
More specifically, the poliovirus is I type virus, and the P1 gene of optimization has such as SEQ ID NO:1
Shown in nucleotide sequence, optimization 3CD gene have the nucleotide sequence as shown in SEQ ID NO:2;
The poliovirus is II type virus, and the P1 gene of optimization has the core as shown in SEQ ID NO:3
The 3CD gene of nucleotide sequence, optimization has the nucleotide sequence as shown in SEQ ID NO:4;
The poliovirus is III type virus, and the P1 gene of optimization has the core as shown in SEQ ID NO:5
The 3CD gene of nucleotide sequence, optimization has the nucleotide sequence as shown in SEQ ID NO:6.
In the step (1), the coexpression vector is to be inserted respectively into the P1 gene and the 3CD gene
pFastBacTMRespectively by a promoter driving transcription at two multiple cloning sites of Dual carrier or Dual-CMV transformation carrier
Obtained recombinant plasmid;
The Dual-CMV transformation carrier is in pFastBacTMP10 promoter engineering is opened for CMV on the basis of Dual carrier
The transformation carrier that mover obtains.
In the step (1), the P1 gene and the 3CD gene are respectively started by one in the recombinant expression carrier
Son driving transcription drives the promoter direction of the P1 gene contrary with the promoter of the 3CD gene is driven.
In the step (1), the competent cell is DH10Bac competent cell, the recombinant virus obtained
Carrier is recombinant baculovirus carrier.
In the step (2), the purpose insect cell is selected from Spodopterafrugiperda ovary cell line sf9, sf21 and powder
Autographa spp embryo cell line High Five.
The invention also discloses recombining spinal cord grey matter disease virus sample particles prepared by the above method.Further,
The recombining spinal cord grey matter disease virus sample particle is I type of poliovirus, II type or III virus-like particle.
The invention also discloses the neutralizing antibody test results of the recombining spinal cord grey matter disease virus sample particle.As a result table
Bright poliovirus sample particle prepared by the present invention has preferable immunogenicity, grinds to the pharmaceutical vaccine of polio
Hair has broad application prospects.
The method of preparation and reorganization poliovirus sample particle of the present invention, successfully makes in insect expression system
For I type of polio, II type and III virus-like particle, shown in the immune neutrality test result of animal level, it is pure
Changing the poliovirus sample particle obtained has higher immunogenicity, and since it does not contain viral nucleic acid, safety
It can be better than traditional attenuation and inactivated vaccine, therefore I type of the polio, II type and III virus-like particle can be applied effectively
In polio vaccine of the preparation based on virus-like particle.
Detailed description of the invention
In order to make the content of the present invention more clearly understood, it below according to specific embodiments of the present invention and combines
Attached drawing, the present invention is described in further detail, wherein
Fig. 1 is I-P1-Dual, II-P1-Dual and III-P1-Dual plasmid and digestion qualification result;
Fig. 2 is I-P13CD-Dual, II-P13CD-Dual and III-P13CD-Dual plasmid and digestion qualification result;
Fig. 3 is Dual-CMV plasmid and digestion qualification result;
Fig. 4 is I-P1-CMV, II-P1-CMV and III-P1-CMV plasmid and digestion qualification result;
Fig. 5 is I-P13CD-CMV, II-P13CD-CMV and III-P13CD-CMV plasmid and digestion qualification result;
Fig. 6 is recombination Poliovirus I sample particle 120KV negative staining electron microscope;
Fig. 7 is II virus-like particle 120KV negative staining electron microscope of recombinant poliovirus;
Fig. 8 is III virus-like particle 120KV negative staining electron microscope of recombinant poliovirus.
Specific embodiment
The selection of 1 expressing gene of embodiment and the optimization design of codon
Saukett plants of Mahoney plants of I type of polio, MEF-1 plants of II type and III type, each virus are chosen respectively
The P1 albumen of strain and the DNA sequence dna of 3CD albumen referring to GenBank, be respectively as follows: NC_002058.3, AY238473.1 and
L23845.1。
It is transformed by Jin Sirui company using wild-type DNA-sequence of the software to above-mentioned coding P1 albumen and 3CD albumen,
Codon avoids the transcription factor that may influence gene expression using the higher codon of frequency of use in insect cell
Combined area, repetitive sequence and RNA higher structure.
P1 protein expression after the optimization of 5 ' end of design and 3 ' ends respectively containing III restriction enzyme site of I restriction enzyme site of EcoR and Hind
Sequence simultaneously carries out gene chemical synthesis, obtains the gene order such as SEQ ID NO of coding I Mahoney plants of P1 albumen of type of polio:
Shown in 1;The gene order of coding II MEF-1 plants of P1 albumen of type of polio is obtained as shown in SEQ ID NO:3;It is encoded
The gene order of III Saukett plants of P1 albumen of type of polio is as shown in SEQ ID NO:5.
3CD protein expression sequence after the optimization of 5 ' end of design and 3 ' ends respectively containing I restriction enzyme site of I restriction enzyme site of Nco and Kpn
Gene chemical synthesis is arranged and carried out, the gene order such as SEQ ID NO:2 of coding I Mahoney plants of 3CD albumen of type of polio is obtained
It is shown;The gene order of coding II MEF-1 plants of 3CD albumen of type of polio is obtained as shown in SEQ ID NO:4;It is encoded
The gene order of III Saukett plants of 3CD albumen of type of polio is as shown in SEQ ID NO:6.
The building of embodiment 2 poliovirus P1 gene and 3CD gene co-expressing carrier
(1)pFastBacTMThe building of Dual coexpression P1 gene and 3CD gene
It is handled respectively using I enzyme of EcoR and III enzyme of Hind (being purchased from NEB) double digestion above-mentioned such as sequence SEQ ID NO:1, SEQ
The P1 protein gene and pFastBac of sequential structure shown in ID NO:3 and SEQ ID NO:5TMDual vector plasmid, in 37 DEG C of water
After bath reaction 4 hours, segment recycling is carried out using the quick plastic recovery kit of miniprep dna segment (being purchased from vast Tyke).By enzyme
After cutting three kinds of P1 nucleotide fragments respectively with pFastBac after digestionTMDual carrier is mixed according to the ratio of molar ratio 9:1, is added
2 × Solution I ligase (is purchased from Dalian treasured bioengineering Co., Ltd), and reaction system is 10 μ L, connects in 16 DEG C of water-baths
Overnight.It takes 10 μ L connection products to convert bacillus coli DH 5 alpha competent cell, and is coated on the LB solid fine jade containing ammonia benzyl resistance
Rouge plate, in 37 DEG C incubator culture 16 hours.It picks from the plate single colonie and is inoculated into the liquid LB training containing 5mL ammonia benzyl resistance
It supports in base, the overnight incubation in the shaking table that 37 DEG C of revolving speeds are 200rpm.It (is purchased from vast using small amount plasmid rapidly extracting kit
Tyke) recombinant plasmid is extracted, obtain I-P1-Dual, II-P1-Dual and III-P1-Dual (plasmid race glue the result is shown in Figure 1, difference
Corresponding swimming lane 1,4,6).Double digestion identification is carried out using I enzyme of EcoR and III enzyme of Hind respectively, result respectively corresponds figure after digestion
Swimming lane 2,5,7, are consistent with expected results in 1.Sequencing company is sent to be sequenced above-mentioned recombinant plasmid, sequencing result is further demonstrate,proved
Real construction of recombinant plasmid success.
It is handled respectively using I enzyme of Nco and I enzyme of Kpn (being purchased from NEB) double digestion above-mentioned such as sequence SEQ ID NO:2, SEQ
The 3CD protein gene of sequential structure shown in ID NO:4 and SEQ ID NO:6 and I-P1-Dual, the II-P1-Dual of above-mentioned acquisition
With III-P1-Dual plasmid, in 37 DEG C after water-bath 4 hours, the quick plastic recovery kit of miniprep dna segment is used to carry out piece
Duan Huishou.By three kinds of 3CD nucleotide fragments after digestion respectively with I-P1-Dual, II-P1-Dual and III-P1-Dual after digestion
Carrier is mixed according to the ratio of molar ratio 9:1,2 × Solution I ligase is added, reaction system is 10 μ L, in 16 DEG C of water-baths
Connection is overnight.10 μ L connection products are taken to convert bacillus coli DH 5 alpha competent cell, and it is solid to be coated on the LB containing ammonia benzyl resistance
Body agar plate, in 37 DEG C incubator culture 16 hours.It picks from the plate single colonie and is inoculated into the liquid containing 5mL ammonia benzyl resistance
In LB culture medium, the overnight incubation in the shaking table that 37 DEG C of revolving speeds are 200rpm.It is extracted using small amount plasmid rapidly extracting kit
Recombinant plasmid, obtaining I-P13CD-Dual, II-P13CD-Dual and III-P13CD-Dual, (plasmid runs cementing fruit and sees Fig. 2, respectively
Corresponding swimming lane 1,4,6).Double digestion identification is carried out using I enzyme of Nco and I enzyme of Kpn respectively, result, which respectively corresponds in Fig. 2, after digestion swims
Road 2,5,7, is consistent with expected results.Sequencing company is sent to be sequenced above-mentioned recombinant plasmid, sequencing result further confirms altogether
Expression vector establishment success.
(2) it is based on pFastBacTMThe transformation of Dual coexpression vector and the building of coexpression vector
In order to further increase the expression yield of poliovirus sample particle, we are by pFastBacTMDual carrier
P10 promoter replace for CMV promoter.Using the primer of the sequence as shown in SEQ ID NO:7 and SEQ ID NO:8, with
PcDNA3.0 plasmid is template, obtains CMV promoter Insert Fragment (sequential structure such as SEQ ID NO:9 institute by PCR amplification
Show).Above-mentioned amplification is handled respectively and is obtained using SmaI enzyme and Sna I enzyme (being purchased from Dalian treasured bioengineering Co., Ltd) double digestion
CMV promoter Insert Fragment and pFastBacTMDual, it is quick using miniprep dna segment in 37 DEG C after water-bath 4 hours
Plastic recovery kit carries out segment recycling.By the CMV promoter nucleotide fragments after digestion and pFastBac after digestionTMDual is carried
Body is mixed according to the ratio of molar ratio 9:1, and 2 × Solution I ligase is added, and reaction system is 10 μ L, is connected in 16 DEG C of water-baths
Take over night.It takes 10 μ L connection products to convert bacillus coli DH 5 alpha competent cell, and is coated on the LB solid containing ammonia benzyl resistance
Agar plate, in 37 DEG C incubator culture 16 hours.It picks from the plate single colonie and is inoculated into the liquid LB containing 5mL ammonia benzyl resistance
In culture medium, the overnight incubation in the shaking table that 37 DEG C of revolving speeds are 200rpm.Weight is extracted using small amount plasmid rapidly extracting kit
Group plasmid obtains Dual-CMV transformation carrier (plasmid runs cementing fruit and sees Fig. 3, corresponding swimming lane 1).SmaI enzyme and Sna are used respectively
I enzyme carries out double digestion identification, and 3 swimming lane 3 of result corresponding diagram, is consistent with expected results after digestion.Send above-mentioned recombinant plasmid to sequencing
Company is sequenced, and sequencing result further confirms CMV promoter transformation vector construction success.
Above-mentioned Dual-CMV is handled using EcoR I enzyme and Hind III enzyme double digestion, carrier is transformed, in 37 DEG C of water-baths
After 4 hours, segment recycling is carried out using the quick plastic recovery kit of miniprep dna segment.By three kinds of P1 nucleosides after digestion in (1)
Acid fragment is mixed with the Dual-CMV transformation carrier after above-mentioned digestion according to the ratio of molar ratio 9:1 respectively, and addition 2 ×
Solution I ligase, reaction system are 10 μ L, overnight in 16 DEG C of water-bath connections.10 μ L connection products are taken to convert Escherichia coli
DH5 α competent cell, and be coated on the LB solid agar plate containing ammonia benzyl resistance, in 37 DEG C incubator culture 16 hours.From flat
Picking single colonie is inoculated into the LB liquid medium containing 5mL ammonia benzyl resistance on plate, in the shaking table that 37 DEG C of revolving speeds are 200rpm
Middle overnight incubation.Recombinant plasmid is extracted using small amount plasmid rapidly extracting kit, obtains I-P1-CMV, II-P1-CMV and III-
P1-CMV (plasmid runs cementing fruit and sees Fig. 4, respectively correspond swimming lane 1,3,6).It is carried out respectively using EcoR I enzyme and Hind III enzyme
Double digestion identification, result respectively corresponds Fig. 4 swimming lane 2,4,7 after digestion, is consistent with expected results.Send above-mentioned recombinant plasmid to sequencing
Company is sequenced, and sequencing result further confirms construction of recombinant plasmid success.
Using three kinds of 3CD protein gene described in (1) as template, NheI is introduced at segment both ends by PCR amplification respectively
The restriction enzyme site of enzyme and KpnI enzyme.Wherein,
PCR upstream primer is 5 '-CTAGCTAGCATGGGACCAGGTTTCGACTA -3 ';
PCR downstream primer is respectively as follows:
5'–CGGGGTACCTTAGAAAGAGTCCAACCAAC–3'(I-3CD);
5'–CGGGGTACCTTAGAAGGAGTCCAACCAAC–3'(II-3CD);
5’–CGGGGTACCTTAGAAACTGTCCAACCATC–3’(III-3CD)。
Using NheI enzyme and KpnI enzyme double digestion handle respectively 3CD protein gene that above-mentioned amplification obtains and I-P1-CMV,
II-P1-CMV and III-P1-CMV plasmid after water-bath 4 hours, use the quick glue reclaim reagent of miniprep dna segment in 37 DEG C
Box carries out segment recycling.By three kinds of 3CD nucleotide fragments after digestion respectively with I-P1-CMV, II-P1-CMV and III-after digestion
P1-CMV carrier is mixed according to the ratio of molar ratio 9:1,2 × Solution I ligase is added, reaction system is 10 μ L, in 16
DEG C water-bath connection is overnight.It takes 10 μ L connection products to convert bacillus coli DH 5 alpha competent cell, and is coated on containing ammonia benzyl resistance
LB solid agar plate, in 37 DEG C incubator culture 16 hours.Single colonie is picked from the plate to be inoculated into containing 5mL ammonia benzyl resistance
LB liquid medium in, in 37 DEG C of revolving speeds be 200rpm shaking table in overnight incubation.Use small amount plasmid rapidly extracting reagent
Box extracts recombinant plasmid, obtain I-P13CD-CMV, II-P13CD-CMV and III-P13CD-CMV (plasmid runs cementing fruit and sees Fig. 5,
Respectively correspond swimming lane 1,3,6).Double digestion identification is carried out using NheI enzyme and KpnI enzyme respectively, result respectively corresponds Fig. 5 after digestion
Swimming lane 2,4,7, is consistent with expected results.Sequencing company is sent to be sequenced above-mentioned recombinant plasmid, sequencing result further confirms
Improved coexpression vector constructs successfully.
The expression of 3 recombinant poliovirus baculoviral of embodiment and purification process
By the I-P13CD- of carrier of expression poliovirus sample granule protein described in previous embodiment 1 and 2
Dual/CMV, II-P13CD-Dual/CMV and III-P13CD-Dual/CMV are respectively according to the Bac-to-Bac table of Invitrogen
Up to system specification, conversion passes through blue hickie after 37 DEG C of incubator culture 48h to competent escherichia coli cell DH10Bac
Screening obtains recombination bacillary viral vector.
The recombination bacillary viral vector that previous step is obtained is transfected using the Cellfectin transfection reagent of Invitrogen
Sf9 insect cell obtains corresponding first generation recombinant baculovirus, i.e. recombinant poliovirus baculoviral, is respectively designated as I-
V1-Dual/CMV, II-V1-Dual/CMV and III-V1-Dual/CMV.Continue to carry out amplification cultivation to above-mentioned generation poison, until obtaining
Obtain I-V3-Dual/CMV of three generations's virus, II-V3-Dual/CMV and the III-V3-Dual/CMV of high virus titer.
The expression of 4 poliovirus sample particle of embodiment and purification process
By I-V3-Dual/CMV of recombinant poliovirus baculoviral, II-V3-Dual/CMV made from embodiment 3 and
III-V3-Dual/CMV connects poison amount infection sf9 suspension cell respectively with 10MOI, with the ESF921 of Expression Systems
Insect cell medium is suspension medium, harvests viral supernatants after being to cultivate 3-4 days in 100rpm shaking table in 27 DEG C of revolving speeds.
The culture supernatant being harvested by centrifugation is concentrated 10 times using 100kD film packet after 0.22 μm of filter membrane filters removal impurity
Concentrate derived above.20% (W/V) sucrose solution of 8mL is added in ultracentrifugation bottom of the tube, concentrate is added in sucrose upper layer.
Supernatant is outwelled after ultracentrifugation 3h, ultracentrifugation precipitation is resuspended with PBST (1 ‰ Tween-20) solution and obtains re-suspension liquid.It will
Re-suspension liquid carries out high speed centrifugation and supernatant is taken to carry out 15%-45% (W/V) sucrose density gradient centrifugation, by ultracentrifugation 5h, from
It is successively taken out under saccharose gradient component (the 600 every pipe of μ L), virus-like particle is rich and in 8-10 component.It collects corresponding
Component carries out concentration desugar processing with 100kD concentration tube to get the poliovirus sample granule protein sample of purifying.
pFastBacTMDual and the expression of improved Dual-CMV carrier are consistent with the method for purified virus sample particle, and by starting
The yield of the virus-like particle of the improved Dual-CMV carrier expression of son is under equal conditions more modified than not
pFastBacTMDual improves four times or more.
The Electronic Speculum inspection of 5 poliovirus sample particle VLPs of embodiment
5 μ L are taken to be added in I type of polio, II type and III virus-like particle that purify in embodiment 4 respectively
1min is adsorbed in plating carbon support film (being purchased from middle mirror tech) uses ddH after filter paper blots plating carbon support film surface residual liquid2O is clear
It washes plating carbon and supports film surface twice, blot ddH2O adds 5 μ L, 2% phosphotungstic acid (being purchased from middle mirror tech) to dye 40s, blots plating carbon
It supports film surface raffinate, uses its morphosis of 120KV transmission electron microscope observation after being placed at room temperature for drying, as a result see respectively attached
Shown in Fig. 6-8.Negative staining electron microscope is the result shows that I type of polio (Fig. 6), II type (Fig. 7) and III type (Fig. 8) virus-like particle are pure
Change the presence of sample virus-like particle of visible diameter about 30nm or so under Electronic Speculum.Result of this example indicate that carrying
The recombinant expression carrier of polio P1 gene and 3CD gene after codon optimization is in insect baculovirus expression system
In, it can successfully pack out the virus-like particle of I type of polio, II type and III type.
The measurement of 6 poliovirus sample particle immunogenicity of embodiment
The poliovirus sample particle prepared in dilution embodiment 4, and Al (OH) is added3Adjuvant mixing.Utilize with
The I virus-like particle of upper purifying was immunized rat twice at first week and third Zhou Jinhang respectively, every time every immune 10 μ g
Or 25 μ g.Import IPV inactivated vaccine is set simultaneously as positive control and the vehicle control without containing virus-like particle sample.Four
To rat, blood was collected after week, collects serum, freezen protective after packing.
Doubling dilution rat blood serum sample, and is diluted to 100TCID50Polio attenuated strain Sabin I mixing it is equal
It is even, it is incubated for 1 hour in 37 DEG C of incubators.It takes the neutralizer of 100 μ l to be added in 96 hole Vero cells, is incubated in 37 DEG C of incubators
It educates 3-4 hours, observes cytopathic effect, that is, CPE.The polio I type virus-like of each 10 μ g is immunized twice as the result is shown
The experimental group of grain can protect completely cell not by virus attack when serum dilutes 1024 times;The spinal cord of each 25 μ g is immunized twice
The experimental group of poliomyelitis I virus-like particle can protect completely cell not by virus attack when serum dilutes 2048 times;Two
The secondary positive controls that fifty-fifty import IPV inactivated vaccine is immunized serum dilute 4096 times when can protect completely cell not by
Virus attack.As it can be seen that the effect of the virus-like particle is preferable and the space of its purifying and optimization is bigger, and virus-like particle
There is higher safety compared to attenuated vaccine and inactivated vaccine.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (7)
1. a kind of preparation method of recombining spinal cord grey matter disease virus sample particle, which comprises the steps of:
(1) the P1 gene and 3CD gene for taking poliovirus are cloned into coexpression vector respectively, then pass through conversion sense
Obtained to express the recombinant viral vector of poliovirus sample particle by state cell;
(2) the recombinant viral vector transfection insect cell obtained with step (1) is obtained after culture containing coding virus-like particle egg
The recombinant virus of white gene;
(3) recombinant virus infection to the host cell that step (2) obtain is expanded to improve virus titer, then inoculation is high
The recombinant virus of titre infects insect cell, to express above-mentioned P1 gene and 3CD gene, and obtains ridge according to conventional purification method
Marrow poliovirus sample particle;
The P1 gene and the 3CD gene are the gene that codon optimization is carried out according to the Preference of host cell;
Wherein, the poliovirus is I type virus, and the P1 gene order of optimization is excellent as shown in SEQ ID NO:1
The 3CD gene order of change is as shown in SEQ ID NO:2;
Alternatively, the poliovirus be II type virus, optimization P1 gene order as shown in SEQ ID NO:3,
The 3CD gene order of optimization is as shown in SEQ ID NO:4;
Alternatively, the poliovirus be III type virus, optimization P1 gene order as shown in SEQ ID NO:5,
The 3CD gene order of optimization is as shown in SEQ ID NO:6.
2. the preparation method of recombining spinal cord grey matter disease virus sample particle according to claim 1, which is characterized in that the step
Suddenly in (1), the coexpression vector is that the P1 gene and the 3CD gene are inserted respectively into pFastBacTMDual carrier
Or the recombinant plasmid respectively obtained by a promoter driving transcription at two multiple cloning sites of Dual-CMV transformation carrier;
The Dual-CMV transformation carrier is in pFastBacTMOn the basis of Dual carrier by p10 promoter engineering be CMV promoter
The transformation carrier of acquisition.
3. the preparation method of recombining spinal cord grey matter disease virus sample particle according to claim 2, which is characterized in that the step
Suddenly in (1), the P1 gene and the 3CD gene are respectively transcribed by a promoter driving in the recombinant expression carrier, are driven
The promoter direction for moving the P1 gene is contrary with the promoter of the 3CD gene is driven.
4. the preparation method of recombining spinal cord grey matter disease virus sample particle according to claim 1 to 3, which is characterized in that
In the step (1), the competent cell is DH10Bac competent cell, and the recombinant viral vector obtained is attached most importance to
Group insect baculovirus carrier.
5. the preparation method of recombining spinal cord grey matter disease virus sample particle according to claim 4, which is characterized in that the step
Suddenly in (2), insect cell is selected from Spodopterafrugiperda ovary cell line sf9, sf21 and cabbage looper embryo cell line High
Five。
6. the recombining spinal cord grey matter disease virus sample particle being prepared by any the method for claim 1-5.
7. recombining spinal cord grey matter disease virus sample particle as claimed in claim 6 is used to prepare prevention and treats the epidemic disease of polio
Purposes in seedling drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610232296.9A CN105802923B (en) | 2016-04-14 | 2016-04-14 | A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610232296.9A CN105802923B (en) | 2016-04-14 | 2016-04-14 | A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105802923A CN105802923A (en) | 2016-07-27 |
CN105802923B true CN105802923B (en) | 2019-07-16 |
Family
ID=56460320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610232296.9A Active CN105802923B (en) | 2016-04-14 | 2016-04-14 | A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105802923B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108130332A (en) * | 2016-12-01 | 2018-06-08 | 上海泽润生物科技有限公司 | Recombinant poliovirus type III virus-like particle |
CN108130333A (en) * | 2016-12-01 | 2018-06-08 | 上海泽润生物科技有限公司 | I virus-like particle of recombinant poliovirus |
US20200368336A1 (en) * | 2017-12-01 | 2020-11-26 | Shanghai Jenomed Biotech Co., Ltd. | Method for preparing personalized cancer vaccine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102559615B (en) * | 2010-12-23 | 2016-09-28 | 上海泽润生物科技有限公司 | EV71 vaccine preparation method and the vaccine prepared by the method |
WO2013098655A2 (en) * | 2011-11-03 | 2013-07-04 | Sentinext Therapeutics Sdn Bhd | Antigens and vaccines directed against human enteroviruses |
US20150044257A1 (en) * | 2012-03-23 | 2015-02-12 | Fred Hutchinson Cancer Research Center | Baculovirus-based enterovirus 71 vlp as a vaccine |
CN102876688A (en) * | 2012-10-15 | 2013-01-16 | 北京工业大学 | Method for preparing recombinant polio I virus-like particles |
CN102876707B (en) * | 2012-10-15 | 2014-05-28 | 北京工业大学 | Preparation method of recombinant poliovirus I-type virus-like particles |
CN103993032A (en) * | 2014-05-05 | 2014-08-20 | 上海博唯生物科技有限公司 | Method for preparing recombinant poliovirus-like particles |
CN104480143B (en) * | 2014-12-04 | 2017-07-04 | 广东华南联合疫苗开发院有限公司 | A kind of preparation method of the carrier and poliovirus sample particle for expressing poliovirus sample granule protein |
-
2016
- 2016-04-14 CN CN201610232296.9A patent/CN105802923B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105802923A (en) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102834507B (en) | For generating the construct of sky picornavirus housing | |
EP3290050B1 (en) | Vaccines directed against human enteroviruses | |
CN103122353B (en) | Porcine O-type foot-and-mouth disease virus recombinant baculovirus as well as preparation method and application thereof | |
CN104480143B (en) | A kind of preparation method of the carrier and poliovirus sample particle for expressing poliovirus sample granule protein | |
CN106867975B (en) | Newcastle disease virus chimeric virus-like particle, vaccine and preparation method | |
CN101695569A (en) | Univalent and bivalent gene engineered subunit vaccine for hand-foot-and-mouth disease and preparation method thereof | |
CN103740758B (en) | Recombinant baculovirus vector, virus like particle, preparation method and use | |
CN106834352A (en) | The polyhedrosis method of parcel carp herpesviral II type antigens is prepared based on baculovirus expression system | |
CN105802923B (en) | A kind of recombining spinal cord grey matter disease virus sample particle and the preparation method and application thereof | |
CN114854697B (en) | Trivalent inactivated vaccine of porcine rotavirus G4-G5-G9 and preparation method and application thereof | |
CN107236747A (en) | Foot and mouth disease virus recombinant virus like-particles and its preparation method and application | |
CN109601007A (en) | A kind of foot and mouth disease virus sample particle vaccines and preparation method thereof | |
CN112048004B (en) | Coxsackie virus B5 type virus-like particle, and preparation method and application thereof | |
CN109234241A (en) | A kind of Coxsackie virus CVA16 type velogen strain CVA16-B6-714 and its application | |
CN111647087B (en) | Chimeric virus-like particle vaccine and preparation method and application thereof | |
CN109207522A (en) | It expresses 3 type of pig circular ring virus and truncates Cap protein recombinant baculovirus and its construction method and primer | |
CN107227311A (en) | Recombination porcine parvovirus like-particles and its preparation method and application | |
CN110256539A (en) | O-shaped foot and mouth disease virus novel gene engineering subunit vaccine | |
CN109207441A (en) | 3 type Cap protein of recombinant baculovirus expression pig circular ring virus and its construction method and primer | |
CN110129348A (en) | Efficiently recombinant DNA carrier, application and the vaccine of preparation foot and mouth disease virus sample particle | |
CN110305852A (en) | Express the building of Porcine epidemic diarrhea virus S1 genetic recombination pseudorabies virus | |
CN103789274A (en) | Rabbit hemorrhagic disease virus recombinant subunit vaccine and preparation method thereof | |
CN108888761A (en) | Express the recombinant baculovirus inactivated vaccine and the preparation method and application thereof of H7N9 subtype avian influenza virus hemagglutinin | |
CN113896773B (en) | Recombinant FCV antigen and feline calicivirus genetic engineering subunit vaccine | |
CN104388437B (en) | Express recombinant defective type adenovirus and its construction method and the application of O-shaped foot and mouth disease virus hollow capsid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |